Term
|
Definition
1)endothelial damage
2) venous stasis
3)Hypercoagulability |
|
|
Term
|
Definition
| reduce ability to form blood clots |
|
|
Term
|
Definition
| Tx and prevent clot formation. Maintain extracorpeal circulation during CABG and renal hemodialysis. Treating clot formation and preventing embolus formation in a-fib. Prevent further clot formation in AMI. |
|
|
Term
|
Definition
| Inhibits formation of thrombin and conversion of fibrinogen to fibrin preventing stable clot formation. Cannot lyse established thrombi. |
|
|
Term
|
Definition
IM/IV/SQ
1/2 life 1.5hrs. weight based. monitor and adjust based on PTT |
|
|
Term
|
Definition
| other anticoagulants, antibiotics (protein binding), antihistamines, nicotine, digoxin, nitroglycerin |
|
|
Term
|
Definition
| BLEEDING, hemorrhage, chest pain, HIT, hematoma |
|
|
Term
| Heparing reversal treatment |
|
Definition
| protamine sulfate(1:1) or FFP's |
|
|
Term
Low Molecular weight heparin
Lovenox
uses |
|
Definition
| DVT prophlyaxsis (sx or medical), tx of DVT or PE, prevent ischemic complications of unstable angina and AMI |
|
|
Term
|
Definition
| Blocks Xa and IIa in the clotting pathway to prevent thrombus formation. preferential to factor X-less affect on platelets than heparin |
|
|
Term
|
Definition
| anticoagulants, antibiotics, herbals (G's) |
|
|
Term
|
Definition
| BLEEDING, hematomas, injection site reactions |
|
|
Term
|
Definition
| FFP, protamine sulfate-doesnt work quite as well |
|
|
Term
|
Definition
| prevention and tx of DVT and PE. Prevent embolic risk in a-fib. Adjunct therapy for prophylaxis of systemic embolism post MI |
|
|
Term
|
Definition
| Interferes w/Vit K clotting factors (II, VII, IX, and X). Clotting factors must be depleted in the blood before anticoagulation eefects take effect |
|
|
Term
|
Definition
| po(iv), highly protein bound. 1/2 life 40hrs. effects in 36-72 hrs. therapeutic in 5-7 days. starting dose 5-10mg for 2-3 days. adjust based on INR. normally want 2-3 |
|
|
Term
|
Definition
| BLEEDING, N/V/D, GI bleed, tast disturbances, hematuria, osteoporosis, "purple toes syndrome" |
|
|
Term
Warfarin
drug interactions |
|
Definition
P450 system-multi interactions
amiodarone/quinolones may increase INR |
|
|
Term
|
Definition
| Vit K and FFP if necessary. <5 and no bleed just lower dose or omit next dose. 5-9 maybe po Vit K 2-5mg. >9 Vit K po 3-5 & repeat in 2448 hr if necessary. >20 Vit K IV 10 and FFP |
|
|
Term
|
Definition
| stroke prophylaxis and systemic embolism prophylaxis in pt w/non-valvular a-fib. DVT/PE prevention |
|
|
Term
|
Definition
| Competitive direct thrombin inhibitor that inhibit both free and clot-bound thrombin. Prevents thrombin-induced platelet aggregation and development of a thrombus by preventing conversion of fibrinogen into firin. |
|
|
Term
|
Definition
| pro-drug, 35% protein bound, not a P450, eliminated renally, 1/2 life 12-17hrs |
|
|
Term
|
Definition
| dyspepsia, BLEEDING, GI HEMMORHAGE, gastritis, wound secretions |
|
|
Term
|
Definition
| Anticoagulants/herbals. P-glycoprotein inducers |
|
|
Term
|
Definition
| If going to have sx-stop 1-2 days before, longer if renal impaired. |
|
|
Term
|
Definition
NO ANTIDOTE
FFP/PRBC, clinical support |
|
|
Term
| Converting from warfarin to pradaxa |
|
Definition
1)stop warfarin
2)wait until INR<2 |
|
|
Term
| Converting from pradaxa to warfarin |
|
Definition
1)based on CrCl
the better the CrCl(>50)earlier start (3 days) warfarin before stopping pradaxa. the lower CrCl(15-30)start warfarin later(1day) before stopping pradaxa |
|
|
Term
| Converting from parentral anticoag to pradaxa |
|
Definition
intermittent dosing: 0-2hr before next (IV/SQ) dose was due
Continuous dosing:give pradaxa at time of d/c |
|
|
Term
| Converting from pradaxa to parentral anticoag |
|
Definition
| wait 12hr CrCl >30 or 24h CrCl<30 after pradaxa before starting |
|
|
Term
|
Definition
| only good for 30days once bottle is open |
|
|
